Blood cancers

How the MURANO trial gives hope for relapsed/refractory CLL

Sponsored by AbbVie Pty Ltd

Although chronic lymphocytic leukaemia (CLL) is one of the most common forms of leukaemia in Australia, it remains incurable.1 While some patients enjoy good and durable responses to first-line therapy, in other patients their disease relapses quickly and can acquire adverse biologic features that render it refractory to treatment with DNA-damaging chemotherapy agents.1 The BCL2 ...

Already a member?

Login to keep reading.

© 2021 the limbic